Context: Current dietary guidelines for cardiovascular disease risk management recommend restricting intake of saturated fatty acids (SFAs). However, the optimal macronutrient profile, in the context of a low-SFA diet, remains controversial. The blood-pressure effect of replacing SFAs in diets with monounsaturated fatty acids (MUFAs) compared with carbohydrate has not been quantified to date. Objective: To synthesize the evidence for the effect of substituting a highcarbohydrate (high-CHO) diet for a high-monounsaturated fatty acid (high-MUFA) diet on blood pressure, a systematic review and meta-analysis of randomized clinical trials in a population without health restrictions was conducted. Data Sources: MEDLINE, EMBASE, and Cochrane Central Register of Controlled Clinical Trials were searched through June 7, 2017. Randomized controlled trials of > 3 weeks duration that assessed the effect of high-MUFA diets in isocaloric substitution for high-CHO diets on systolic blood pressure (SBP) and diastolic blood pressure (DBP) were included. Data Extraction: Data were pooled using the generic-inverse variance method with random effects models and expressed as mean differences (MDs) with 95% confidence intervals (CIs). Heterogeneity was assessed by Cochran Q statistic and quantified by the I 2 statistic. The quality of the evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Results: Fourteen trials (n ¼ 980 participants) were included in the analysis. Comparatively, the high-MUFA diets in isocaloric substitution for high-CHO diets did not demonstrate a greater reduction in blood pressure (SBP: MD, À0.08 mmHg [95%CI, À1.01 to 0.84], P ¼ 0.86; DBP: MD ¼ 0.01 mmHg [95%CI, À0.73 to 0.75], P ¼ 0.98). The overall quality of the evidence was assessed as moderate. Conclusions: In the context of low SFAs, high-MUFA diets in isocaloric substitution for high-CHO diets did not affect blood pressure in individuals with and without hypertension. Large-scale trials achieving higher MUFA targets are required to support these findings. ClinicalTrials.gov ID: NCT02626325.
INTRODUCTION
A long-standing controversy exists regarding what macronutrient profile in a diet promotes optimal health. Among the nutrients that have accrued the most discussion are dietary fats, with particular emphasis on the amount and type consumed. Over the last several decades, dietary recommendations have evolved, from the introduction by Keys et al 1 of saturated fatty acids (SFAs) as the key to the coveted reduction in the quantity of total fat, 2 to, most recently, a more flexible approach that suggests the elimination of this longstanding limit on total fat. 3 Despite the lack of consensus on optimal macronutrient ratios, major health agencies continue to unanimously advocate a diet low in SFAs to reduce cardiovascular disease (CVD) risk. [4] [5] [6] The need to provide recommendations for alternative macronutrients to SFAs in the diet has been again emphasized by the American Heart Association Presidential Advisory. 7 Although carbohydrates (CHO) have been long exploited as a substitute in reduced-fat diets, the success of oil-rich Mediterranean-type dietary patterns in lowering CVD incidence 7 has prompted the new consideration of dietary approaches within the framework of a higher-fat intake. This viewpoint is supported by the large Prospective Urban and Rural Epidemiology (PURE) cohort study, which found higher total fat intake to be associated with a 23% lower risk of total mortality (hazard ratio, 0.77; 95% confidence interval [CI] , 0.67-0.87; P < 0.001), with similar risk reductions across individual types of fat. 8 Blood pressure (BP) is a key vector for CVD prevention and is among the strongest risk factors for CVD. It may be differentially impacted depending on macronutrient intake ratios. Diets high in CHO or monounsaturated fatty acids (MUFAs) may produce changes in endothelial function and hemodynamic outcomes via the cholesterol-driven axis, the insulinemic response pathway, or oxidative stress. [9] [10] [11] Previous studies that have compared the effects of high-MUFA and high-CHO diets on BP have had inconsistent findings. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] As a result, major guidelines for managing BP are vague or do not contain recommendations on macronutrient substitutions. The recent lifestyle guidelines from the American Heart Association, which recommend replacing 10% CHO with healthy fat (8% MUFAs) to decrease systolic BP (SBP) by 1 mmHg, based on OMNIHeart data, are the only exception. 23 Without a comprehensive evaluation and comparison of replacement macronutrients, it remains unclear whether individuals would achieve a more favorable BP level through the replacement of CHO with MUFAs, irrespective of the source. To the authors' knowledge, this is the first systematic review and meta-analysis of exclusively randomized controlled trials (RCTs) that investigated the effect on BP of isocaloric substitution of a high-MUFA diet for a high-CHO diet.
METHODS

Design
This systematic review and meta-analysis followed the Cochrane Handbook for Systematic Reviews of Intervention. 24 Results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Appendix S1 in the Supporting Information online). 25 The review protocol is available at ClinicalTrials.gov (NCT02626325).
Search strategy and data sources MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through June 7, 2017. Manual search of references of the included studies supplemented the electronic search. Randomized controlled trials were identified using the search terms "monounsaturated fat* OR unsaturated fatty acids OR nut OR olive oil OR canola oil OR carbohydrate* OR dietary carbohydrates OR highcarbohydrate diet AND blood pressure OR systolic blood pressure OR diastolic blood pressure OR arterial pressure OR mean arterial pressure" (Table S1 in the Supporting Information online).
Study selection
The PICOS criteria for inclusion are listed in Table 1 . Studies were considered for analysis if they were RCTs that compared the effect of high-MUFA diets in isocaloric substitution for high-CHO diets on BP measurements. No restrictions were given to the health status of participants. Trials were included if they had a followup period > 3 weeks. No language restrictions were imposed. Exclusion criteria included trials that were conducted in animals, observational trials, unpublished studies, and trials that did not compare high-MUFA with high-CHO diets as they impacted on BP.
Data extraction
Two independent reviewers extracted data using a standardized proforma. Relevant data included information on authorship, publication year, study design (crossover/parallel), duration, run-in, washout, blinding (single/double/open-label/not available), sample size, participant characteristics (age, sex, healthy status, baseline BP, and body mass index [BMI]), diet percentage intake, compliance (food record/diary/questionnaire/ad libitum/test foods returned/plasma markers/dietary counseling), funding source (agency/industry), and setting (outpatient/inpatient).
The primary outcomes were mean differences (MDs) in end-of-treatment SBP and diastolic blood pressure (DBP). Change values from baseline in SBP and DBP were used when end-of-treatment values were not available. 26 Measures of mean arterial pressure were not included in the analysis because mean arterial pressure, a calculation derived from an individual's SBP and DBP values (DBP/[SBPÀDBP]), was reported for only 1 study. The standard error (SE) of the MD was used to impute the 95% confidence interval for each comparison. To impute SE (MD) in parallel studies, standard formulas were used. 24 For crossover studies, the pooled correlation coefficient between the 2 groups was used to impute the SE (MD) 27 ; a conservative correlation coefficient of 0.5 was assumed for missing standard deviations (SDs). Authors were contacted when data were not available, and studies were deemed irretrievable if there was no response after 3 attempts. 28 
Risk-of-bias assessment
Each study was assessed for risk of bias by 2 independent reviewers using the Cochrane Risk of Bias Assessment tool. Domains of assessment included sequence generation, allocation concealment, blinding, outcome data, and reporting. 24 Trials were considered "high risk" if they contained methodological flaws that may have affected the results, "low risk" if the flaw was deemed inconsequential, and "unclear risk" if insufficient information was provided to determine. Disagreements were resolved by consensus.
Grading the evidence
To assess the overall quality and strength of evidence, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used. 29 Evidence was rated as being of "very low," "low," "moderate," or "high" quality. By default, the included RCTs received an initial grade of high, which could then be downgraded based on a series of prespecified criteria, including risk of bias (weight of studies show risk of bias assessed by the Cochrane Risk of Bias tool), inconsistency (substantial unexplained heterogeneity, I
2 > 50%, P < 0.01), indirectness (presence of factors that limited the generalizability of the results), imprecision (the 95%CIs for effect estimates were wide or crossed a minimally important difference for benefit or harm), and publication bias (evidence of small-study effects from visual inspection or Egger's and Begg's test, P < 0.05).
Data syntheses
Data were analyzed using Review Manager, v5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The MDs were calculated by end-of-treatment SBP and DBP values of the high-CHO diet group subtracted from the end-of-treatment values of the high-MUFA diet group. The MDs were reported with 95%CIs. The MDs 6 SE (MD) derived from each study were pooled and analyzed using the generic inverse variance method with random effects model (DerSimonian-Laird), and results were compared with a fixed-effects model. 24 A 2-sided P < 0.05 was set as the level of significance for comparisons of MDs. Data from all crossover studies were analyzed using paired analyses. 27 Interstudy heterogeneity was assessed with the Cochran Q statistic at a < 0.10 and quantified by the I 2 statistic, where I 2 < 50%, ! 50% and < 75%, and ! 75% were considered to be evidence of "moderate," "substantial," and "considerable" heterogeneity, respectively. 24 The confidence interval for I 2 was generated using the heterogi command in STATA v.13.1 (StataCorp, College Station, TX, USA).
Sources of heterogeneity were explored through sensitivity and subgroup analyses. Continuous and categorical a priori subgroup analyses were conducted for duration, study design (crossover/parallel), funding (agency/agency-industry), BP measure (manual/digital), baseline BP, baseline BMI (kg/m 2 ), CHO and MUFA intake at baseline defined as percentage of daily energy (%E), change in CHO and MUFA intake from baseline (%E), difference in MUFA and CHO between groups (%E), and difference in fiber intake (%E). Meta-regressions were performed (P < 0.05) to assess the significance of subgroup effects using STATA software. A post hoc subgroup analysis according to followup duration was also performed in Review Manager using the random-effects model to further assess the effect of trials with duration < 12 weeks and ! 12 weeks in length. To determine whether any single trial exerted particular influence on the overall results, sensitivity analyses were performed in which each trial was removed from the meta-analysis and the effect size was recalculated using the remaining trials. Sensitivity analyses were also undertaken using correlation coefficients 0.25, 0.50, and 0.75 to test the robustness of the results using different correlation coefficients in paired analyses of crossover trials.
A dose-response analysis was performed using STATA software. A linear meta-regression was performed for every %E MUFA substituted for %E CHO on SBP and DBP. A nonlinear dose estimate was performed using restricted cubic spline meta-regression with 3 knots. Meta-regression was also performed to test whether there were differences between specified dose thresholds of CHO (%E) displaced by MUFA (%E).
Publication bias was evaluated by visual inspection of funnel plots and quantitatively assessed using the Egger's and Begg's tests, where P < 0.05 was considered evidence of small-study effects. If publication bias was identified, then the missing study was imputed to adjust for funnel plot asymmetry using the Duval and Tweedie trim-and-fill method. Figure 1 summarizes the study selection protocol. The search identified 5829 articles, of which 5794 were excluded on the basis of duplicates, irrelevant titles, and abstracts. A total of 35 studies were reviewed in full, and of those, 14 trials (n ¼ 980 participants) were included for analysis.
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RESULTS
Search results
Trial characteristics
The characteristics of the included trials are summarized in Table 2 . 13, [16] [17] [18] 21, 22, 26, [32] [33] [34] [35] [36] [37] [38] Trials were conducted in various populations, including type 2 diabetes (n ¼ 4 trials), metabolic syndrome (n ¼ 3 trials), hypertension/prehypertension (n ¼ 2 trials), hypercholesterolemia (n ¼ 1 trial), hyperlipidemia (n ¼ 1 trial), gestational diabetes (n ¼ 1 trial), insulin resistance (n ¼ 1 trial), type 1 diabetes (n ¼ 1 trial), individuals having at least 1 factor for increased risk of diabetes (obesity, family history diabetes mellitus, diabetes mellitus gestational, previous high blood glucose, or triglycerides) (n ¼ 1 trial), and healthy (n ¼ 1 trial). A crossover design was used in 57% of the trials, and a parallel design was used in 43%. The median age of participants was 54. , respectively. The trials were funded by agency (71%) and agency-industry (29%). The median follow-up was 12 weeks (IQR, 6-13 weeks). To measure compliance, food records were used in 10 trials (71%), diaries in 1 trial (7%), and measurement of test food returned in 1 trial (7%); method was not specified in 2 trials (14%). Digital BP measures were used in 5 trials (36%), manual BP measures were used in 3 trials (21%), and unspecified BP measures were used in 6 trials (43%). Double-blinding was used in 1 trial (7%), and single-blinding was used in 3 trials (16%); 1 trial (7%) was open-label; and information on blinding was not provided for 9 trials (64%) ( Table 2) . Table S2 in the Supporting Information online provides the characteristics of the background diets, which were reported for 57% of the trials (n ¼ 8 trials Intervention diets showed significant differences (P < 0.05) in CHO, MUFAs, and fat intake between high-CHO and high-MUFA groups (Table S3 in the Supporting Information online). Median quantities of CHO were 53.1%E (IQR, 49.7%E-55.3%E) for the high-CHO group and 44.8%E (IQR, 41.0%E-47.3%E) for the high-MUFA group. The MUFA median quantities were 10.0%E (IQR, 9.3%E-11.0%E) and 20.0%E (IQR, 18.4%E-22.3%E) for the high-CHO and high-MUFA groups, respectively (Table S3 in the Supporting Information online). No significant differences were observed in polyunsaturated fat, SFA, and protein intake between the high-CHO and high-MUFA diets. Similarly, there were minimal differences in fiber (median, 32.5 vs 32.1 g/d) and alcohol intake (median, 1.8% vs 1.9%) between the high-CHO and high-MUFA diets, respectively. Similar kilocalories were consumed in both the high-CHO (median, 1951 kcal; IQR, 1737-2121 kcal) and high-MUFA groups (median, 2063 kcal; IQR, 1959-2151) (P > 0.05) ( Table S3 in the Supporting Information online). Exact kilocalories were not provided for 1 trial, 36 but eucaloric interventions were indicated for both diet groups. Sodium, potassium, and calcium intake were reported for 2 trials (14%), 13, 32 and magnesium intake was reported for 1 trial (7%). 13 Although intake did not differ drastically, higher sodium and calcium and lower potassium from the high-MUFA diet were reported for 1 trial 32 , and higher sodium, potassium, calcium, and magnesium from the high-CHO diet were reported for the other trial. 13 
Risk of bias
Using the Cochrane Risk of Bias Tool ( Figure S1 in the Supporting Information online), individual trials were judged as having a high, low, or unclear risk of bias for the domains measured. In each of the domains for random sequence generation, allocation concealment, and selective reporting data, the majority of trials (81%) were judged as having an unclear risk of bias. In the 2 domains for blinding, half of the trials (50%) had a low risk of bias, 3 trials (19%) had a high risk of bias in blinding of participants and personnel, and the remainder of the trials had an unclear risk of bias. In the domain for incomplete outcome data, the majority of trials (56%) had a low risk of bias, but 2 trials (13%) had a high risk of bias. 
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Participant status and study characteristics of 14 randomized controlled trials (n ¼ 980 participants) comparing the effect of high-monounsaturated fatty acid and high-carbohydrate diets on systolic and diastolic blood pressure. Data are given as mean 6 SD or mean (range). A dash (-) indicates that the details were not specified.
Abbreviations: BMI, body mass index; BP, blood pressure; C, crossover; DB, 
Side effects
Two trials provided data on collateral effects from the treatment diets. Appel et al 22 reported poor appetite, dry mouth, fullness, and bloating from both the high-CHO and high-MUFA diets; Jenkins et al 17 described
food allergies and abdominal discomfort from the high-MUFA diet.
Effect on systolic and diastolic blood pressure The overall results were not changed when a fixedeffects model was used.
A priori subgroup analyses
Continuous meta-regression analyses showed that SBP was significantly modified by follow-up duration; for every additional week in duration, SBP was lower by 0.23 mmHg (P ¼ 0.03), favoring the high-CHO group (Table S4A in the Supporting Information online). Continuous subgroup analysis also suggested that with each percentage increase in difference of CHO (%E) between the intervention groups, the less favorable the SBP outcome was on the high-CHO diet in comparison, as indicated by a P value bordering significance (b ¼ À0.30 mmHg; P ¼ 0.05). The overall effect on DBP was not modified by continuous subgroups analyses (Table  S4B in the Supporting Information online). Categorical subgroup analyses suggested a significant difference in SBP and DBP between subgroups with follow-up duration < 12 weeks compared with subgroups with > 12 weeks (P ¼ 0.04) (Table S5A and S5B in the Supporting Information online). Categorical subgroup analyses also suggested a difference between subgroup with change in MUFA from baseline > 5.9%E compared with < 5.9%E (P ¼ 0.05) ( Table S5B in the Supporting Information online).
Post hoc subgroup analyses
Subgroup analysis according to follow-up duration ( Figures S2 and S3 in the Supporting Information online) suggested significant subgroup differences for SBP and DBP between follow-up of < 12 weeks and followup of > 12 weeks (P ¼ 0.02 and P ¼ 0.03, respectively). Summary effect estimates within each subgroup, however, were not statistically significant (P > 0.05) for both outcomes.
Sensitivity analyses
Systematic removal of individual trials did not alter the results. Sensitivity analyses using different correlation coefficients in paired analyses of crossover trials Figure 2 Forest plot of 14 randomized controlled trials (n 5 980 participants) investigating the effect of high-monounsaturated fatty acid and high carbohydrate diets on systolic blood pressure. The pooled effect estimate on systolic blood pressure is represented by the black diamond. Values are mean differences with 95% confidence intervals determined using the generic inverse-variance randomeffects model. Interstudy heterogeneity was quantified by I 2 at a significance of P < 0.10. n ¼ number of participants in each treatment group. Abbreviations: CI, confidence interval; High-CHO, high-carbohydrate; High-MUFA, high-monounsaturated fatty acid.
(0.25, 0.50, and 0.75) did not alter the significance of the pooled effect size (P > 0.05), nor did it alter heterogeneity (I 2 ) (data not shown).
Dose-response analysis
The dose-response analysis did not reveal any linear associations between increasing dose of MUFA substitution for CHO (in the range of 5.5%E to 19%E) and SBP and DBP ( Figure S4 in the Supporting Information online). There was also no evidence of a nonlinear effect on SBP (P ¼ 0.26) and DBP (P ¼ 0.72) ( Figure S5 in the Supporting Information online). Outcomes were not significantly different (P > 0.05) when tested for above or below individual substitution dose thresholds of MUFA for CHO (%E) ( Table S6 in the Supporting Information online).
Publication bias
Visual inspection of funnel plots (Figure 4 ) revealed no obvious asymmetry. This was supported by Egger's and Begg's tests, which did not reveal significant small-study effects for either outcome (P > 0.05).
GRADE assessment
Using the GRADE system, the overall quality of the summarized evidence for both SBP and DBP was assessed as moderate (Table S7 in the Supporting Information online). With the inclusion of RCTs, the evidence started at high quality. A downgrade was made for indirectness due to unreported levels of potassium and sodium intake and the inconsistent report of carbohydrate quality, which may have had confounding effects and may limit the generalizability of the results, respectively. There were no downgrades made for other domains: risk of bias, inconsistency, imprecision, and publication bias.
DISCUSSION
The present systematic review and meta-analysis pooling results from 14 RCTs (n ¼ 980 participants) revealed no significant differences in SBP (P ¼ 0.86) and DBP (P ¼ 0.98) from a high-MUFA diet in isocaloric substitution for a high-CHO diet over a median duration of 12 weeks.
To the authors' knowledge, 1 other systematic review and meta-analysis has previously explored BP in high-MUFA diets compared with high-CHO diets. 39 The study investigated both randomized and nonrandomized trials in a heterogeneous patient population and found that the high-CHO intake resulted in greater SBP and DBP values by 1.3 mmHg (P ¼ 0.001) and 0.9 mmHg (P < 0.01), respectively, relative to a high-MUFA diet, using a less conservative fixed-effect model. Conversely, in the present analysis, data from double the number of trials were updated and analzyed; nevertheless a difference in BP effects was not demonstrated, irrespective of the model used (random vs fixed-effects model).
To date, clinical research on optimizing macronutrient substitutions for SFAs has focused on evaluating several surrogate measures of CVD, primarily lipids as a proximal metabolic target. Replacing energy intake Figure 3 Forest plot of 14 randomized controlled trials (n 5 980 participants) investigating the effect of high-monounsaturated fatty acid and high-carbohydrate diets on diastolic blood pressure. The pooled effect estimate on diastolic blood pressure is represented by the black diamond. Values are mean differences with 95% confidence intervals determined using the generic inverse-variance randomeffects model. Interstudy heterogeneity was quantified by I 2 at a significance of P < 0.10. n ¼ number of participants in each treatment group. Abbreviations: CI, confidence interval; High-CHO, high-carbohydrate; High-MUFA, high-monounsaturated fatty acids.
from CHO with cis-MUFAs has been shown to improve the lipid profile. Specifically, 1%E replacement has been associated with a reduction in the ratio of total/HDL-C (mean change, À0.03; 95%CI, À0.04 to À0.02; P < 0.001). 40 Aside from blood lipids, guidelines on optimizing MUFA and CHO marconutrient targets for glycemic control in individuals with type 2 diabetes are not well defined, although they vaguely imply the benefit of MUFA-rich, Mediterranean-style diets. 4, 41 The present findings on BP may be surprising in the context of current dietary CVD recommendations, 5, 6, 23 given that the 2013 American Heart Association/American College of Cardiology Guidelines indicated a reduction of SBP by 1 unit in adults with BP in the range of 120-159/80-95 mmHg, after replacing 10%E CHO with MUFA (ie, 8%E MUFA), on the basis of the OmniHeart trial. 23 In the subgroup analysis herein, however, displacement of CHO with MUFA (>9%E) in the background of prudent or Dietary Approaches to Stop Hypertension (DASH)-like dietary patterns did not produce a similar benefit. Vascular function and BP are thought to be strongly influenced by both dietary CHO and fat. 42 High-CHO loads have been consistently associated with adverse endothelial function in a postprandial setting, with several studies finding nonfavorable declines in endothelial-dependent vasodilatation and endogenous antioxidant defense mechanisms following an oral glucose load in healthy individuals and in those with type 2 diabetes. [43] [44] [45] Moreover, it has been shown in an early study that a single meal rich in MUFA from oleic acid can impair postprandial endothelial function relative to an isoenergetic high-CHO meal. 46 Oleic acid comprises the majority of MUFAs in high-MUFA foods, which include vegetable oils, nuts, and oil seeds. It has been suggested that endothelial dysfunction may be driven by oxidized lipoproteins, 47, 48 linking lipemia to atherosclerosis and vascular dysfunction. 49, 50 Conversely, MUFA administration has also been implicated in having a beneficial effect on atherogenic alterations, including inflammatory markers, 51, 52 coagulation factors, [53] [54] [55] and endothelial activation, 56, 57 factors that may play a role in BP regulation. The effect of high-MUFAs on BP was assessed in the large PREDIMED study, which compared versions of the well-advocated Mediterranean diet enriched with either virgin olive oil or nuts as MUFA sources and found beneficial reductions in SBP from both arms compared with a low-fat diet from timepoints as early as 3 months 58 to 1 year. 59 Although the BP effects of high MUFA or CHO intake relative to respective baseline BPs were not quantified in the present study, the resultant BP indices following either diet were comparable. Continuous subgroup analyses suggested a positive association between study follow-up and SBP, suggesting that with longer trial duration, SBP may be more favorable on high-CHO diets compared with high-MUFA diets. Although this trend was observed in categorical analysis as well, the observed between-group difference is modest. The relevance of this trend is unclear and difficult to interpret because the studies with the longest duration (24 wk) were inconsistent in the quality of CHO. One trial incorporated staple CHO sources (rice, potatoes, bread), 35 whereas another trial did not indicate quality of CHO. 36 Several other studies with long follow-ups that favored the high-CHO diet had investigated low-glycemic index (GI) foods for 16 weeks 38 or fiber-rich CHO for 12 weeks. 16 The high-quality CHO intake may be partially driving the favorable association observed with a long-term high-CHO diet. Future research in this area should not only define carbohydrate quality but also compare high-quality CHO, such as low-GI or high-fiber diets, with high-MUFA diets during extended term feeding. Differences in study outcomes investigating MUFA in place of CHO may be due to this discrepancy The difference in CHO intake (%E) between the high-CHO and high-MUFA groups may differentially affect BP. Continuous subgroup analysis suggests that the greater the difference in CHO (%E) intake between the 2 intervention groups, the less favorable the SBP on a high-CHO diet is (À0.30 mmHg; 95%CI, À0.60 to 0.00; P ¼ 0.05). Despite all studies in the present analysis indicating a statistically significant difference in CHO intake between the intervention groups, the change may not have translated to a clinically significant difference in BP as observed in the pooled effect size. Similarly, the categorical analyses revealed that it may be necessary to consider the obtained change in MUFA (%E) from baseline, as greater changes in MUFA may favor greater reduction in DBP relative to CHO diets (P ¼ 0.05). Moreover, the majority of trials (67%) that did not find a difference in SBP and DBP between interventions had an MUFA intake (%E) that was < 21%, 16, 17, 26, 32, 35, 37 which is the macronutrient target of the high-MUFA diet profile that lowered BP compared with a high-CHO OMNI-HEART diet. 22 Given the metabolic health benefits that have been recently associated with MUFA intake, 60 higher MUFA proportions (> 20%E) may be necessary to bring about reductions in BP. In dose-response analysis, however, there were no linear associations for SBP or DBP for every %E of MUFA substituted for CHO. Considering the narrow range of intake across the trials (5.5%E-19%E), future directions should investigate higher target macronutrient intakes (%E) as well as higher target differences (%E) when comparing high-CHO with high-MUFA diets.
One of the strengths of this meta-analysis is that body weight remained stable across all studies, thus minimizing the confounding effect of weight loss on BP. Importantly, %E from SFAs (n ¼ 13), PUFAs (n ¼ 13), protein (n ¼ 13), alcohol (n ¼ 8), and fiber (n ¼ 7) were not different between high-CHO and high-MUFA diets in the majority of the studies. For several studies (n ¼ 4), however, higher fiber ingestion (difference of 9-17.5 g/d) was reported in the high-CHO diet compared with the high-MUFA diet, suggesting some variation in CHO quality. 13, 16, 21, 38 Additionally, moderate heterogeneity was detected in the overall analysis (SBP: I 2 ¼ 0%; DBP:
indicating very little variability among studies for both outcomes.
Although this meta-analysis did not demonstrate a difference in BP associated with either diet, its limitations should be considered. Micronutrient intake, including that of sodium 61 and potassium, 62 may be important for BP regulation in individuals with elevated BP. Sodium and potassium intake were reported for only 2 of the 14 studies 13, 32 included in this metaanalysis; the intakes were not notably different between intervention diets but were inconsistent between the 2 trials. Given their potential to confound clinical values, these nutrients should be quantified in future studies. In addition, a high percentage of articles presented an unclear risk of bias in the following domains: random sequence generation (81%), allocation concealment (81%), selective reporting (75%), blinding of participants and personnel (50%), and blinding of outcome assessment (50%). Insufficient information was reported for these studies to make a fair judgment on whether the trials are limited by the presence of bias. A few studies were judged as having a high risk of bias for blinding of participants and personnel based on the high likelihood that participants altered dietary patterns with the knowledge of allocated intervention, which may have affected study results. 16, 38 Although the overall risk of bias across the studies did not warrant a downgrade in quality, the validity of several study results and the inconsistency of reporting across trials should be considered.
It is also important to evaluate the quality of CHO as part of the background diet because complex and simple CHO will produce differential cardiometabolic effects, including vascular responses and changes in BP. 42 Although all reductions of SFAs in the diet should be accompanied by an isoenergetic replacement with other macronutrients, increased consumption of refined CHO has been raised as a concern. 63 The quality of CHO may be an important modifier of BP response within high-CHO dietary regimens, with high-quality sources of CHO such as low-GI CHO possibly yielding advantages. However, the present meta-analysis did not differentiate the effects of CHO quality. The categorical subgroup analysis addressed this factor but did not show a difference in BP between diets incorporating healthy sources (fruits and vegetables) and diets incorporating conventional CHO sources (bread, potato, rice).
The overall evidence was graded as moderate quality according to the GRADE assessment. A serious downgrade was made for indirectness, due to the incomplete report of micronutrient intake and the inconsistent report of CHO quality, which may sizably alter study results.
CONCLUSION
This review and meta-analysis found that high-CHO and high-MUFA diets in the context of low SFAs did not differentially affect BP, as assessed using clinical BP measurements in a participant population of various health statuses. Although guidelines advise for the replacement of SFAs with other macronutrient sources for the reduction of CVD risk, the present pooled analysis does not suggest isocaloric substitution of MUFA for CHO to be more favorable for BP reduction. Future meta-analyses could consider adopting the individual participant data approach. 64 Moreover, larger highquality substitution trials should be conducted with more attention paid to CHO quality and consideration given to higher MUFA (%E) targets.
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